Comparisons of persistence and durability among three oral antidiabetic therapies using electronic prescription-fill data: The impact of adherence requirements and stockpiling

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 6, 2011, Pages 813-819

  Greevy Jr , R A ^a,b   Huizinga, M M ^c,d,e   Roumie, C L ^a,b   Grijalva, C G ^b   Murff, H ^a,b   Liu, X ^a,b   Griffin, M R ^a,b  

^a Tennessee Valley Healthcare System   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; AGED; ARTICLE; BODY MASS; DIABETES MELLITUS; ELECTRONIC MEDICAL RECORD; ELECTRONIC PRESCRIBING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; AGED; COHORT STUDIES; ELECTRONIC HEALTH RECORDS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MEDICATION ADHERENCE; METFORMIN; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RESEARCH DESIGN; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS;

EID: 81355139588     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.228     Document Type: Article

References (19)

1. Caracciolo, E.A. et al. Diabetics with coronary disease have a prevalence of asymptomatic ischemia during exercise treadmill testing and ambulatory ischemia monitoring similar to that of nondiabetic patients. An ACIP database study. ACIP Investigators. Asymptomatic Cardiac Ischemia Pilot Investigators. Circulation 93, 2097-2105 (1996).
2. Grundy, S.M. et al.; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112, 2735-2752 (2005). (Pubitemid 41532612)
3. American Diabetes Association Clinical Practice Recommendations 2001. Diabetes Care 24(suppl. 1), S1-S133 (2001).
4. Summary of revisions for the 2006 Clinical Practice Recommendations. Diabetes Care 29(suppl 1), S3 (2006).
5. Bolen S. et al. Comparative effectiveness and safety of diabetes medications for adults with type 2 diabetes. Agency for Healthcare Research Quality publication no. 07-EHC010-EF, 2007.
6. Kahn S.E. et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355, 2427-2443 (2006). (Pubitemid 44903747)
7. Huizinga, M.M. et al. Glycemic and weight changes after persistent use of incident oral diabetes therapy: a Veterans Administration retrospective cohort study. Pharmacoepidemiol. Drug Saf. 19, 1108-1112 (2010).
8. Corrao, G., Romio, S.A., Zambon, A., Merlino, L., Bosi, E. & Scavini, M. Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: a population-based cohort study in Italy. Eur. J. Clin. Pharmacol. 67, 289-299 (2011).
9. Grégoire, J.P., Sirois, C., Blanc, G., Poirier, P. & Moisan, J. Persistence patterns with oral antidiabetes drug treatment in newly treated patients-a population-based study. Value Health 13, 820-828 (2010).
10. Andrade S.E., Kahler K.H., Frech F. & Chan K.A. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol. Drug Saf. 15, 565-574 (2006). (Pubitemid 44336271)
11. Sokol, M.C., McGuigan, K.A., Verbrugge, R.R. & Epstein, R.S. Impact of medication adherence on hospitalization risk and healthcare cost. Med. Care 43, 521-530 (2005). (Pubitemid 40847288)
12. Hepke, K.L., Martus, M.T. & Share, D.A. Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am. J. Manag. Care 10, 144-151 (2004). (Pubitemid 38332389)
13. Hertz, R.P., Unger, A.N. & Lustik, M.B. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employersponsored health insurance. Clin. Ther. 27, 1064-1073 (2005). (Pubitemid 41262464)
14. Lau, D.T. & Nau, D.P. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 27, 2149-2153 (2004). (Pubitemid 39167177)
15. Stephens, J.M., Botteman, M.F. & Hay, J.W. Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature. J. Manag. Care Pharm. 12, 130-142 (2006). (Pubitemid 47400606)
16. Dailey, G., Kim, M.S. & Lian, J.F. Patient compliance and persistence with antihyperglycemic therapy: evaluation of a population of type 2 diabetic patients. J. Int. Med. Res. 30, 71-79 (2002). (Pubitemid 34618725)
17. Dailey, G., Kim, M.S. & Lian, J.F. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin. Ther. 23, 1311-1320 (2001). (Pubitemid 32804123)
18. Hynes, D.M. et al. Veterans' access to and use of Medicare and Veterans Affairs health care. Med. Care 45, 214-223 (2007).
19. International Classification of Diseases, Ninth Revision, Clinical Modification (Public Health Service, US Dept. of Health and Human Services, Washington, DC, 1988).